- CEO
- Shih Kien Djeng
- Full Time Employees
- 104
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Address
- No. 02-01, 1 Biopolis Drive Singapore CE Singapore 138622
- IPO Date
- Feb 16, 2024
- Business
- Singapore Institute of Advanced Medicine Holdings Ltd. (SAM Holdings) is a Singapore-based investment holding company that provides advanced medical diagnostics, treatments, radiation therapy, and medical oncology services primarily focused on cancer care and related conditions. Founded in 2011 and headquartered at 1 Biopolis Drive, #02-01 Amnios, Singapore 138622, the company operates through subsidiaries including Asia HealthPartners, Advanced Medicine Imaging, and Proton Therapy SG, with facilities in Biopolis, Orchard Road's Lucky Plaza, and Mount Elizabeth Orchard Medical Center. Its core products and services encompass medical diagnostics and treatments such as cancer-related diagnostics, theranostics, general diagnostics, health screening, aesthetic services, general practice, plastic surgery, endoscopy, and imaging modalities including MRI, CT, PET/CT, X-ray, mammography, and ultrasound; radiation therapy offerings include proton beam therapy, photon radiation therapy, stereotactic radiosurgery, and medical oncology; as well as nuclear medicine services supported by an in-house radiopharmaceutical laboratory for on-demand production. The company serves patients across Singapore, targeting complex medical challenges in oncology, neurodegenerative, and cardiovascular diseases through a multidisciplinary team of specialists and cutting-edge technologies like those from Philips, Varian, and Siemens. In recent developments, SAM Holdings forged a strategic partnership with EnGeneIC in June 2024 to advance EDV-based cancer therapeutics and theranostics across Asia, including exclusive sales rights and shared profits; signed medical service agreements with Raffles Hospital and collaborates with the National Cancer Centre Singapore on research and drug trials; completed a S$5.24 million debt conversion and S$0.69 million share placement in 2025 to strengthen its balance sheet and pursue new opportunities like rights issues; and fully launched its Biopolis proton therapy center in 2023 following COVID-19 delays, enhancing its comprehensive radiotherapy capabilities.